PharmaResearch (CEOs Kang Ki-seok and Kim Thinkyou), a company specializing in regenerative medicine, announced earlier this month that it held a launch symposium for REJURAN® HB Plus at Four Seasons Hotel in Singapore.
The symposium aimed to share the technological advancements and clinical experiences of REJURAN® HB Plus with local aesthetic experts and medical professionals.
Dr. Michael J. Kim, a key opinion leader (KOL) for REJURAN®, moderated the event, while presentations were led by Dr. Ho-sung Choi from Korea, along with local medical professionals Dr. Shenthilkumar Naidu and Dr. Ngiam Juzheng.
Dr. Ho-sung Choi first introduced the DOT™ (DNA Optimizing Technology) and the various treatment methods using REJURAN® HB Plus. DOT™ is a patented technology by PharmaResearch that optimizes DNA extracted from salmon for human applications. REJURAN® HB Plus incorporates the DOT™ PN (polynucleotide) ingredient.
Following this introduction, local medical professionals Dr. Shenthilkumar Naidu and Dr. Ngiam Juzheng elaborated on the efficacy and clinical experiences of REJURAN® HB Plus.
PharmaResearch spokesperson stated, "Singapore serves as a crucial hub in the Asian medical aesthetics market, and through this launch, the distinguished clinical strengths and excellent efficacy of REJURAN® HB Plus have been impressed upon healthcare professionals in Singapore." They added, "We will further strengthen marketing activities for the REJURAN® lineup, including in Singapore, to rapidly broaden our footprint in the global skin booster market."
REJURAN® HB Plus is a skin booster that combines the main ingredient of the original REJURAN®, PN (polynucleotide), with the moisturizing component HA (hyaluronic acid). It also includes the local anesthetic lidocaine, allowing for less painful treatments compared to the original REJURAN®.
PharmaResearch is a pioneering biopharmaceutical company dedicated to enhancing the quality of life for humanity through regenerative medicine. With a diverse portfolio encompassing medicines, medical devices, cosmetics, and supplements, PharmaResearch focuses on leveraging its core ingredients, DOT™ PDRN and DOT™ PN. These active tissue regenerative substances are powered by DOT™, an exclusive DNA fragments optimization technology safeguarded by a suite of patents. PharmaResearch is located in Seongnam, South Korea, and its US subsidiary, PharmaResarch USA is located in Costa Mesa, California, US.
For more information about PharmaResearch and its innovative initiatives, visit http://pharmaresearch.co.kr/en
Media Contact
Company Name: PharmaResearch USA
Contact Person: Sangjin Choi
Email: Send Email
Country: United States
Website: http://pharmaresearch.co.kr/en
